Click Here to return To Results

 

Copaxone's Effect on MRI-Monitored Disease in Relapsing MS is Reproducible and Sustained Neurol 59:1284-1286, Wolinsky,J.S.,et al, 2002 See this aricle in Pubmed Article Abstract All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European-Canadian MRI trial entered an open-label extension with quarterly cli nical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the en tire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.

Related Tags

(click to filter results - removes previous filter) cop 1 MRI MRI,abnormal MRI,serial multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of treatment of neurologic disorder

Click Here to return To Results